Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema

Cicardi, Marco; Banerji, Aleena; Bracho, Francisco; Malbrán, Alejandro; Rosenkranz, Bernd; Riedl, Marc; Bork, Konrad; Lumry, William; Aberer, Werner; Bier, Henning; Bas, Murat; Greve, Jens; Hoffmann, Thomas K; Farkas, Henriette; Reshef, Avner; Ritchie, Bruce; Yang, William; Grabbe, Jürgen; Kivity, Shmuel; Kreuz, Wolfhart; ... (2010). Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. New England journal of medicine NEJM, 363(6), pp. 532-41. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa0906393

Full text not available from this repository. (Request a copy)

Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Pichler, Christiane

ISSN:

0028-4793

Publisher:

Massachusetts Medical Society MMS

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:10

Last Modified:

16 Jul 2018 14:55

Publisher DOI:

10.1056/NEJMoa0906393

PubMed ID:

20818888

Web of Science ID:

000280552700007

URI:

https://boris.unibe.ch/id/eprint/1681 (FactScience: 203559)

Actions (login required)

Edit item Edit item
Provide Feedback